Literature DB >> 6464130

The use of Lassa fever convalescent plasma in Nigeria.

J D Frame, G P Verbrugge, R G Gill, L Pinneo.   

Abstract

Lassa fever convalescent plasma (LFCP) has been administered to 27 patients in hospitals at Jos and Vom, Nigeria. Among serologically or virologically confirmed cases of Lassa fever (LF) given plasma on or before the 10th day, all eight survived, as did two of three possible LF cases. Of eight patients given LFCP after the 10th day, five died, as did all three possible LF cases. LFCP was also administered to five patients subsequently shown not to have LF, and to a suspected case contact; all survived without complications of therapy. There were 15 cases of LF during this time who did not receive plasma; 11 survived. Most cases of LF who received plasma and survived showed a rapid response to therapy, in contrast with the gradual recovery in those who did not receive LFCP.

Entities:  

Mesh:

Year:  1984        PMID: 6464130     DOI: 10.1016/0035-9203(84)90107-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  32 in total

1.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

2.  Patients with suspected Lassa fever in London during 1984.

Authors:  R T Emond
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-14

3.  Exchange transfusion of a patient with fulminant Lassa fever.

Authors:  D Cummins; D Bennett; S J Machin
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

4.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Authors:  Chad E Mire; Robert W Cross; Joan B Geisbert; Viktoriya Borisevich; Krystle N Agans; Daniel J Deer; Megan L Heinrich; Megan M Rowland; Augustine Goba; Mambu Momoh; Mathew L Boisen; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; Karla A Fenton; James E Robinson; Luis M Branco; Robert F Garry; Thomas W Geisbert
Journal:  Nat Med       Date:  2017-09-04       Impact factor: 53.440

Review 5.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

6.  Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers.

Authors:  Andrew M Lee; Jillian M Rojek; Anette Gundersen; Ute Ströher; Jean-Marc Juteau; Andrew Vaillant; Stefan Kunz
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

Review 7.  Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.

Authors:  Ashli M Heustess; Melissa A Allard; Dorothea K Thompson; Pius S Fasinu
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-28

Review 8.  Management of Lassa Fever: A Current Update.

Authors:  Ammar Alli; Juan Fernando Ortiz; Stephanie P Fabara; Amrapali Patel; Taras Halan
Journal:  Cureus       Date:  2021-05-02

9.  Experimental Morogoro Virus Infection in Its Natural Host, Mastomys natalensis.

Authors:  Chris Hoffmann; Stephanie Wurr; Elisa Pallasch; Sabrina Bockholt; Toni Rieger; Stephan Günther; Lisa Oestereich
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

Review 10.  Immune responses and Lassa virus infection.

Authors:  Marion Russier; Delphine Pannetier; Sylvain Baize
Journal:  Viruses       Date:  2012-11-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.